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Adjuvant chemotherapy for oesophagogastric cancer with epirubicin,
cisplatin and infusional 5-fluorouracil (ECF): a Royal Marsden pilot
study
A Bamias, D Cunningham, V Nicolson, A Norman, M Hill, M Nicolson, M O'Brien, A Webb
and A Hill
The Cancer Research Campaign Section ofMedicine and the GI Unit, The Institute ofCancer Research, and The Royal Marsden
Hospital, Downs Road, Surrey SM2 5PT, UK.
Sminmary Previous trials of adjuvant chemotherapy for oesophagogastric cancer have shown only modest or
no improvement in survival. However, the regimens used in these studies produce low response rates in
patients with advanced disease. ECF is a new regimen which results in higher response rates and may therefore
be more effective in the adjuvant setting. Twenty-nine patients who had undergone a potentially curative
resection for oesophagogastric carcinoma were treated with ECF [epirubicin 50 mg m-2 and cisplatin
60 mg m -', given every 3 weeks for six courses combined with continuous-infusion 5-fluorouracil (5-FU) at
200mg m2 for 18 weeks]. The median age was 52.5 years. Three patients had oesophageal tumours, 14 had
tumours of the oesophagogastric junction (OGJ) and 12 had gastnrc tumours. All were adenocarcinomas apart
from one undifferentiated carcinoma. One patient had stage I disease, nine stage II, 17 stage III and two stage
IV. The mean number of chemotherapy cycles per patient was 5.2 (range 2-8). The median follow-up was 8.4
months (1.5-36.3 months). Eleven patients relapsed during follow-up (38%). One patient had an anastomotic
recurrence and ten patients distant metastases. Overall 3 year survival was 61.5% (95% confidence interval
42-79); 3 year survival in stage II was 50% (21.2-86.3) and in stage III 65.6% (40-86). Chemotherapy was
well tolerated, with grade 3/4 toxicity as follows: leucopenia 13.5%, nausea and vomiting 10%, diarrhoea
3.5%, infection 3.5% and thrombocytopenia 3.5%. There were no treatment-related deaths. We conclude that
ECF can be administered safely as adjuvant treatment to patients with surgically resected gastro-oesophageal
carcinoma. The results, especially in patients with stage Ill disease, are encouraging and support the
investigation of this regimen within a prospective randomised trial.
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Although the incidence of gastric cancer has declined steadily
over the past 50 years (Coggon and Inskip, 1994), it remains
the second most common tumour worldwide and the fourth
commonest in Europe. Surgery alone is the treatment of
choice for tumours confined to the mucosa and submucosa,
achieving cure rates of more than 80% (Thompson and Van
Heerden, 1993). When disease is locally advanced (T3/T4)
curative surgery is possible in only a minority of patients
(Rahamin and Cham, 1993; McCulloch, 1994) and disease
recurrence after potentially curative resection in locally
advanced gastric cancer occurs in approximately 80% of the
patients within 5 years of surgery (Girling, 1992; Weese and
Nussbaum, 1992).
Gastric cancer is one of the more chemosensitive cancers
of the GI tract, evidenced by the relatively high response
rates to chemotherapy in patients with inoperable or meta-
static disease (MacDonald et al., 1980; Wils et al., 1986;
Lerner et al., 1992; Findlay et al., 1994). In the adjuvant
setting, however, the value of chemotherapy is less clear cut,
with several randomised trials failing to show any significant
benefit from adjuvant chemotherapy (Wils and Bleiberg,
1988; Allum et al., 1989; Coombes et al., 1990). A recent
meta-analysis of 11 randomised studies (Hermans et al.,
1993) was initially reported supporting the conclusion that
adjuvant chemotherapy offers no survival benefit. However,
the amended results (Hermans and Bonencamp, 1994), in-
cluding two further trials, showed a small but statistically
significant effect in favour of adjuvant therapy. Moreover,
the regimens employed in these studies could be expected to
produce responses in only 20-40% of patients with advanced
disease (Cocconi, 1994), while second-generation regimens,
such as ECF and FAMTX (5-fluorouracil, doxorubicin,
methotrexate), produce much higher response rates (Wils et
al., 1986; Findlay et al., 1994). Thus, adjuvant therapy with
these combinations may significantly improve the outcome.
Oesophageal cancer is less common than gastric cancer but
its incidence is rising (Coggon and Inskip, 1994). The prog-
nosis is similarly poor, with 5 year survival after curative
resection less than 20% for stages II and III. The addition of
radiotherapy to surgery has not resulted in any significant
benefit in patients with advanced disease (Ellis and Cunning-
ham, 1994). However, chemotherapy and radiotherapy in
locally advanced disease has proved more effective than
radiotherapy alone (Sichy et al., 1990; Herscovic et al., 1992),
suggesting that chemotherapy may have a significant role.
The ECF regimen, developed by the GI Unit of the Royal
Marsden Hospital, consists of epirubicin, cisplatin and con-
tinuous infuision of 5-FU. A phase II study of 139 patients
with locally advanced and metastatic gastro-oesophageal
cancer showed high response rates (70%), with approxi-
mately 13% of the patients achieving complete remission
(Findlay et al., 1994). For this reason we conducted a pilot
study of ECF given in the adjuvant setting to assess the
feasibility of administering this chemotherapy to patients
following major surgery to the upper gastrointestinal tract.
Patiets and methods
Patients
Between 14 March 1990 and 18 January 1994, 29 patients
were treated with adjuvant ECF. All had histologically
confirmed oesophageal, OGJ or gastric carcinoma. Tumours
of the lower oesophagus were classified as oesophageal car-
cinomas when at least 50% was extending into the
oesophagus, while tumours with at least 50% of their extent
in the stomach were classified as OGJ carcinomas. In all
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cases macroscopic cleance of disease was achieved by
surgery and resection were free of tumour on his-
topathological examinaton. Staging according to the TNM
system was based on the findings during the operation and
histopathological examination of the resected specmen.
Before trial entry, patients were required to have a normal
computerised tomographic (CT) scan ofthe thorax, abdomen
and pelvis, a creatinine clarance of more than 40ml min-l
and a bilirubin of less than 30mmol 1'. All patients were
treated between 6 and 10 weeks from surgery and gave their
written consent to participate in the study, which was
approved by the Royal Marsden Research Ethics Committee.
Intravenous access
Chemotherapy was given through a double-lumen indwelling
catheter (Quintin, USA) placed in the subclavian vein via a
subcutaneous tunnel under local anastesia (Stacey et al.,
1990). Warfarin (1 mg daily) was adninisered throughout
the treatment to prevent line thrombosis. Lines were removed
under local anaesthetic after the termination of treatment.
Chemotherapy
The first patient received eight cycles of ECF. Subsequently,
it was planned that each patient would receive six cycles of
chemotherapy. 5-FU was i as a continuous intra-
venous infusion at a dose of 200mgmin2 using a portable
battery-powered pump (Infumed no. 350, Medex, USA, or
Graseby no. M26, Graseby, UK). All patients received pro-
phylactic nystatin and sucralphate suspensions to prevent
mouth ulceration. Patients developing diarrhoea or mucositis
had a treatment break until these symptoms resolved and
would restart at a 50 mgm 2 dose reduction. A dose reduc-
tion of 100mgm-2 was used for patients with toxicity of
grade 3 or 4. Patients developing palmar-plantar syndrome
were given pyridoxine 50mg t.d.s. and if this toxicity did not
improve, 5-FU was discontinued for 1 week and restarted at
a dose of 150mgm-2.
Cisplatin was inisd at 60mgm2 every 3 weeks
with stamndard hydration (Findlay et al., 1994). Dose
Table I Patient characteristics
Age sye) (range)
Sex
Site
OGJ
Gastic
Histology
Adenocarcinoma
Undifferentiated
Differentiation
Good
Moderate
Poor
Undifferentiated
Lauren classification
Ud
Intestinal
Diffuse
TNM staging (pathological)
Gastric + OGJ
lb T2NOMO
II T2NlMO
T3NOMO
IHa T2N2MO
T3NIMO
Illb T3N2MO
IV T2NIMI
T3NOMI
Oesopbeal
In T3NIMO
52.5 (22-75)
M22 F7
3
14
12
28
2
10
16
1
6
15
8
4
5
4
6
4
1
1
modification for cisplatin was based on glomerular filtration
rate (GFR), which was estimted using r'CrJEDTA clear-
ance. If GFR was greater than or equal to 60 mlmin-', full
cisplain dose was given; if GFR was 40-60mlmin-' the
dose ofcisplatin in mg equald the GFR value in ml min-';
if the GFR was lower than 40 ml min-' the patient was not
eligible. Epirubicin at 50mg m 2 was given as a bolus intra-
venous injection every 3 weeks. If the white cell count was
less than 2.0 x 1091-' and/or plateklts less than 100 x 10' I'
when treatment was due, epirubicin and cisplatin were
delayed for 1 week or until myelosuppression had resolved. A
second episode of treatment delay due to myelosuppression
or an episode of neutropenic sepsis required a 25% dose
reduction of epirubicin on subsequent treatments.
Mild infections of the indwelling catheters were treated
with oral flucloxacilin or according to bacteriology results.
Indwelling catheters were removed in the following situa-
tions: septiaemia due to line infection, line infection
worsening in spite of appropriate antibiotic treatment, line
thrombois, intolerable shoulder pain and incorrect place-
ment of the line.
Statistics
Data were collected and entered prospectively onto the GI
Unit database. Survival data were examined using the pro-
duct limit method of Kaplan and Meier and differences in
survival were assessed using the log-rank test.
Re Is
Patients
Patient characteristics are shown in Table I. The median
follow-up was 8.4 months (1.5-36.3 months). In one case
preoperative radiotherapy was admiised to the area of
the primary tumour. All patients had T2 or T3 tumours. In
two cases omental diseas was found during the operation
but as all macroscopic disease was removed and no evidence
of further dissemination was found during the operation or
on the post-operative CIT scan, treatment was considered as
adjuvant. AU tumours were adenocarcinomas apart from one
undifferentiated gastric carcinoma.
Toxicity
A total of 151 cycles were aministered. The mean number of
cycles per patient was 5.2 (2-8 cycles). The percentage of the
planned dose inistered was 5-FU 96%, cisplatin 98%
and epirubicin 98%. The most common side-effects asso-
ciated with chemotherapy are shown in Table H. Toicity
was graded according to the common toxicity criteria (Rubin
and Wasserman, 1988). Alopecia was observed in the
majority of the patients (82%). The other non-haema-
tological side-effects were: nausea and/or vomiting (44%),
diarrhoea (45.5%), stomatitis (34%), infection (24%), pal-
mar plantar erytma (20%) and neuropathy (7%). These
side-effects were mild in most cases. Grade 3 or 4 non-
haematological toxicity was observed in only five cases out of
51 recorded toxicities (10%). Transient loss of taste was
reported by ten patients (34.5%). Haematological toxicity
was mild with only five out of the 21 (24%) grade 3 or 4.
Leucopenia was observed in 17 cases (58.5%) and throm-
bocytopenia in four cases (14%). Infections of indwelling
catheters occurred in six cases (21%) leading in two patients
to catheter roval and in one patient the catheter had to be
removed due to venous thrombosis. In all three cases the
catheter were successfully re-nserted.
Seven cycles (4.8%) were delayed due to toxicity, which
was haematological in four, mucositis in one, nausea and
vomiting in one and infection without leucopenia in the
other. Only two patients required admission for complica-
tions associated with chemotherapy: one patient with post-
operative intra-abdominal abscesses before chemotherapy.oadw ECFforossopha ocancer
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Table U Toxicity associated with ECFchemotherapy (expressed asworst toxicity observed
in each patient). Toxicity was graded according to the common toxicity criteria
Grade
0 1 2 3 4
No. (%) No. (%) No. (%) No. (%) No. (%}
Nausea and vomiting 16 (56) 5 (17) 5 (17) 3 (10) 0 (0)
Diarrhoea 16 (54.5) 6 (21) 6 (21) 1 (3.5) 0 (0)
Stomatitis 19 (66) 5 (17) 5 (17) 0 (0) 0 (0)
Infection 22 (76) 1 (3.5) 5 (17) 1 (3.5) 0 (0)
Palmar-plantar 23 (80) 3 (10) 3 (10) 0 (0) 0 (0)
Neuropathy 27 (93) 2 (7) 0 (0) 0 (0) 0 (0)
White blood cells 12 (41.5) 5 (17) 8 (28) 3 (10) 1 (3.5)
Platelets 25 (86) 1 (3.5) 2 (7) 1 (3.5) 0 (0)
developed sepsis without leucopenia following the second
cycle of ECF which resolved with intravenous antibiotics; the
other patient was admitted dehydrated owing to vomiting
following the third cycle of ECF and was managed with
intravenous fluids and antiemetics. In four patients (14%)
treatment was prematurely discontinued. These included the
previously described patient with intra-abdominal abscesses
and three patients who received four cycles of ECF before
stopping chemotherapy due to repeated diarrhoea, nausea
and vomiting and lethargy, respectively. There were no
treatment-related deaths.
Survival
Eleven patients (38%) relapsed between 5 and 39 months
after surgery in the following sites: anastomosis one, Kruken-
berg's tumours three, peritoneum two, distant lymph nodes
one, brain one, liver one, lung one and bone one. All patients
who relapsed had T3 tumours, except for one who had a T2
tumour. The stage of the disease was II in one case, stage III
in eight and stage IV in one. Of the two patients with
omental disease before surgery one relapsed 1 year after
surgery with penrtoneal disease and the other died 9 months
after surgery.
Eight patients (27.5%) died during follow-up, six because
of progressive disease. One patient had an unknown cause of
death and the other patient had post-operative intra-
abdominal sepsis, tolerated only two courses of chemo-
therapy and died of septic complications 6 months after
diagnosis with no evidence of recurrence on CT scan or liver
biopsy. Figure 1 shows the overall survival and at the time of
analysis the median survival had not been reached. One year,
2 year and 3 year survivals are shown in Table m. Statistical
analysis showed no association of relapse with site, stage,
tumour extent (T2 or T3), histology, differentiation or
Lauren classification. Survival was not associated with the
stage of the disease.
Dbusion
The role of adjuvant chemotherapy after curative resection of
advanced oesophageal or gastric cancer is unclear. Ran-
domised studies have failed to show a consistent benefit from
adjuvant chemotherapy although many of the regimens
employed are not particularly effective in advanced disease
(Wils et al., 1991). A meta-analysis of 13 randomised trials
using such regimens has, however, shown a significant benefit
in favour of chemotherapy, but the effect is small (Hermans
and Bonencamp, 1994). More recently developed combina-
tions have superior response rates in advanced disease and
are under investigation in the adjuvant setting.
Our phase II trial of ECF has shown similar results to
these second-generation regimens but with less toxicity, par-
ticularly myelotoxicity (Findlay et al., 1994). The main
feature of ECF is the use of continuous infusion of 5-FU,
which results in a considerable increase in the dose intensity
Table m Median survival following adjuvant chemotherapy with
ECF
Survival % (range)
1 year 2 years 3 years
All cases (n = 29) 81 (63-94)' 61.5 (42-79) 61.5 (42-79)
Stage H (n = 9) 50 (21 -86) 50 (21-86) 50 (21 -86)
Stage III (n = 17) 94 (71-99) 65.6 (40-86) 65.6 (40-86)
a95% confidence intervals.
0
1-
b-
0 .0
._
0
- 0 1 2 3
Time since surgery (years)
4
Fge 1 Survival of patients treated with adjuvant ECF
chemotherapy (n = 29).
of this drug compared with FAM (5-fluorouracil, dox-
orubicin, mitomycin C) and FAMTX. Continuous infusion
of 5-FU has also proved to be less toxic than bolus adminis-
tration in advanced colorectal carcinoma. (Lokich et al.,
1989) with diarrhoea and stomatitis the dose-limiting toxicity.
This relative lack of toxicity with high dose intensity makes
infusional 5-FU an attractive component of an adjuvant
combination regimen.
Toxicity with ECF was mild. Treatment was prematurely
discontinued in only four cases, one of which was a conse-
quence of delayed post-operative complications. Admission
to hospital was necessary in only two cases. Although bone
marrow toxicity was common, it was usually mild and it was
not life-threatening. Additionally, the use of indwelling
catheters was associated with minimal toxicity and good
compliance. These results compare favourably with those
reported with FAMTX and EAP (Kelsen et al., 1992; Lerner
et al., 1992). Bone marrow toxicity represents a serious com-
plication of these regimens, particularly since patients receiv-
ing them have often undergone major thoracic or abdominal
surgery, not infrequently associated with post-operative com-
plications. The effect of ECF treatment on survival cannot be
accurately evaluated from this pilot study, but the 3 year
survival suggests that there may be a survival benefit,
especially in stage III disease.
In conclusion, ECF is feasible to administer in the
adjuvant setting to patients with oesophagogastric adenocar-
n v AAdjwa EC:Ffor cMp1
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cinomas. The results in stage III disease are particularly
encouraging and support the investigation of this regimen in
a prospective randomised trial comparing surgery plus
chemotherapy with surgery alone. Such a study has just been
launched by the Medical Research Council (MAGIC trial)
and includes pre- and post-operative courses of ECF in the
chemotherapy arm.
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